$2.50
7.75% day before yesterday
Nasdaq, Jun 27, 10:00 pm CET
ISIN
US47010C3007
Symbol
JAGX
Sector
Industry

Jaguar Health, Inc. Stock price

$2.50
-1.91 43.31% 1M
-23.25 90.29% 6M
-22.75 90.10% YTD
-88.00 97.24% 1Y
-35,187.50 99.99% 3Y
-166,722.50 100.00% 5Y
-1,623,037,497.50 100.00% 10Y
-2,402,662,497.50 100.00% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.21 7.75%
ISIN
US47010C3007
Symbol
JAGX
Sector
Industry

Key metrics

Basic
Market capitalization
$3.3m
Enterprise Value
$34.7m
Net debt
$31.4m
Cash
$5.7m
Shares outstanding
670.0k
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.29 | 0.23
EV/Sales
3.00 | 2.42
EV/FCF
negative
P/B
0.39
Financial Health
Equity Ratio
18.29%
Return on Equity
-393.98%
ROCE
-137.79%
ROIC
-83.06%
Debt/Equity
8.68
Financials (TTM | estimate)
Revenue
$11.6m | $14.3m
EBITDA
$-30.2m | $-23.7m
EBIT
$-32.0m
Net Income
$-39.7m | $-16.3m
Free Cash Flow
$-29.7m
Growth (TTM | estimate)
Revenue
13.91% | 22.40%
EBITDA
0.40% | 18.24%
EBIT
0.78%
Net Income
-3.68% | 57.73%
Free Cash Flow
2.27%
Margin (TTM | estimate)
Gross
82.34%
EBITDA
-261.07% | -
EBIT
-277.33%
Net
-343.92% | -113.72%
Free Cash Flow
-256.69%
More
EPS
$-63.40
FCF per Share
$-44.26
Short interest
2.77%
Employees
49.00
Rev per Employee
$240.00k
Show more

Is Jaguar Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Jaguar Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Jaguar Health, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Jaguar Health, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Jaguar Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
12 12
14% 14%
100%
- Direct Costs 2.04 2.04
4% 4%
18%
9.51 9.51
19% 19%
82%
- Selling and Administrative Expenses 26 26
15% 15%
222%
- Research and Development Expense 16 16
12% 12%
138%
-30 -30
0% 0%
-261%
- Depreciation and Amortization 1.88 1.88
6% 6%
16%
EBIT (Operating Income) EBIT -32 -32
1% 1%
-277%
Net Profit -40 -40
4% 4%
-344%

In millions USD.

Don't miss a Thing! We will send you all news about Jaguar Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jaguar Health, Inc. Stock News

Neutral
Accesswire
3 days ago
Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of value SAN FRANCISCO, CA / ACCESS Newswire / June 26, 2025 / Jaguar Health, Inc. ( NASDAQ:JAGX ) ("Jaguar" or "the Company"), announced today that its Board of Directors has unanimously authorized the Company to include cryptocurrency as a treasury reserve asset. "Cryptocurrencies continue to gai...
Neutral
Accesswire
4 days ago
Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogs Jaguar is exploring the possibility of approval of Canalevia for treatment of general diarrhea in dogs in the EU based on the statistically significant data from a completed study Diarrhea is one of the most common reasons own...
Neutral
Accesswire
5 days ago
Company's CEO, board members, other C-suite members, and institutional and accredited investors are participants in the extension of the bridge financing SAN FRANCISCO, CA / ACCESS Newswire / June 24, 2025 / Jaguar Health, Inc. ( NASDAQ:JAGX ) ("Jaguar" or "the Company"), announced today that the maturity date has been extended from June 30, 2025 to January 30, 2026 for approximately $2.57 mill...
More Jaguar Health, Inc. News

Company Profile

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Head office United States
CEO Lisa Conte
Employees 49
Founded 2013
Website jaguar.health

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today